Physician profile
Neil Singer
NPI 1043277478
$1,404.11
in general payments reported to CMS, 2019-2025
14 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $294 · 2021: $114 · 2022: $253 · 2023: $205 · 2024: $137 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $450.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $451.60 | 2019-2023 | Prolia, Evenity |
| Astrazeneca Pharmaceuticals Lp | $445.21 | 2019-2025 | Breztri, Airsupra |
| Amarin Pharma, INC. | $140.67 | 2019 | |
| Janssen Pharmaceuticals, INC | $124.20 | 2019-2022 | |
| Allergan, INC. | $47.12 | 2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $42.44 | 2022 | |
| Abbvie INC. | $38.77 | 2022-2023 | Linzess |
| Lilly USA, LLC | $20.18 | 2023 | Mounjaro |
| Radius Health, INC. | $19.37 | 2024 | Tymlos |
| Pfizer INC. | $18.33 | 2024 | |
| Paratek Pharmaceuticals, INC. | $17.66 | 2025 | Nuzyra |
| Novartis Pharmaceuticals Corporation | $16.22 | 2019 | |
| Philips North America LLC | $11.27 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Singer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.